UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): January 14, 2015

ZIOPHARM Oncology, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware	**001-33038**	**84-1475672**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

One First Avenue, Parris Building 34, Navy Yard Plaza
Boston, Massachusetts **02129**
(Address of Principal Executive Offices) **(Zip Code)**

(617) 259-1970
(Registrant's telephone number, including area code)

Not applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Item 7.01 Regulation FD Disclosure

On January 14, 2015, ZIOPHARM Oncology, Inc., or the Company, will present the attached discussion of The Future of Cancer Therapy at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, being held on January 12 - 15, 2015.

A copy of the above referenced presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. This information, including the information contained in the press release furnished as Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any of the Company's filings, whether made before or after the date hereof, regardless of any general incorporation language in any such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	Presentation of the Company dated January 14, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZIOPHARM Oncology, Inc.

By: /s/ Kevin G. Lafond
Name: Kevin G. Lafond
Title: Vice President, Chief Accounting Officer and Treasurer

Date: January 14, 2015

INDEX OF EXHIBITS

Exhibit No.	Description
99.1	Presentation of the Company dated January 14, 2015


ZIOPHARM Oncology
The Future of Cancer Therapy
JP Morgan 33rd Annual Healthcare Conference
January 2015
www.ziopharm.com

Forward-Looking Statements

ZIOPHARM Oncology

This presentation contains certain **forward-looking information about ZIOPHARM Oncology** that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our ability to successfully develop and commercialize our therapeutic products, our ability to expand our long-term business opportunities; financial projections and estimates and their underlying assumptions; and future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: whether any of our therapeutic candidates will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any of our therapeutic candidates will be successfully marketed if approved; whether our DNA-based biotherapeutics discovery and development efforts will be successful; our ability to achieve the results contemplated by our collaboration agreements; the strength and enforceability of our intellectual property rights; competition from pharmaceutical and biotechnology companies; the development of and our ability to take advantage of the market for DNA-based biotherapeutics; our ability to raise additional capital to fund our operations on terms acceptable to us; general economic conditions; and the other risk factors contained in our periodic and interim reports filed with the SEC including, but not limited to, our annual report on Form 10-K for the fiscal year ended December 31, 2013 and Quarterly Report on Form 10-Q for the period ended September 30, 2014, and other filings with the SEC, which are available at www.sec.gov. Our audience is cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

ZIOPHARM Oncology

ZIOPHARM Oncology, Inc.

THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center
Making Cancer History®

JP Morgan

Jonathan Lewis, M.D., Ph.D., CEO, ZIOPHARM Oncology

Ad-RTS-IL-12 Overview

Adenoviral mediated controlled delivery of Interleukin-12

ZIOPHARM Oncology



ZIOPHARM has leading expertise in clinical translation of designer cytokines

Oral Veledimex Precisely Controls the Expression of IL-12

ZIOPHARM Oncology



Next steps for IL-12

Moving to active immunotherapy

ZIOPHARM Oncology

- ZIOPHARM has leading expertise in clinical translation of designer cytokines
- RheoSwitch Therapeutic System® platform for conditional expression of
  - Immunoreceptors
  - Cytokines
- ZIOPHARM is partnering with MDACC in Boston and Houston

ZIOPHARM Oncology, Inc.

INTREXON®

JP Morgan

Greg Frost, Ph.D., SVP Health Sector, Intrexon Corporation

Non-Viral Adoptive Cellular Therapies

ZIOPHARM Oncology

INTREXON and ZIOPHARM Announce Exclusive Licensing Agreement with MD Anderson Cancer Center for Chimeric Antigen Receptor (CAR) T-Cell and Associated Technologies for the Development of Non-Viral Adoptive Cellular Therapies

THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center
Making Cancer History®

ZIOPHARM Oncology, Inc.

INTREXON®

Resulting in Point of Care and Off the Shelf Cellular Solutions

ZIOPHARM Oncology

Point of Care Product

- Integration with RheoSwitch® control of T cell propagation and specificity in patients
- Facilitates a no-culture solution to manufacturing

Off the Shelf Product

- Genetically modify and edit T cells to express CAR and eliminate TCR
- AttSite® landing pads for precision genetic engineering
- iPSC processing technologies combined with LEAP® to engineer an HLA-matched product

Recombinases and Transposases

Key Technology Synergies

ZIOPHARM Oncology

Technology	Intrexon / ZIOPHARM / MD Anderson
RheoSwitch Therapeutic System®	Most advanced family of ligands and switches available for dynamic range, safety, and spatial/temporal control
Non-Viral Integration Platform	First-in-human testing of *Sleeping Beauty* system in hematopoietic cells
UltraVector®	Industrialized assembly and screening of multigenic DNA modules for synthetic biology
Adoptive Cell Therapy	Expertise in development and implementation of novel immunotherapy trials

Established clinical pipeline for adoptive cellular therapies

...With Traditional Oncology Reimbursement for Cellular Therapies

ZIOPHARM Oncology

Avoids Acute PBM Pressures Driven by Cost Density



THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center
Making Cancer History®

ZIOPHARM Oncology, Inc.

INTREXON®

JP Morgan

Laurence J.N. Cooper, M.D., Ph.D., Professor of Pediatrics at MD Anderson

THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center
Making Cancer History®

The technology being discussed has been licensed by MD Anderson to Ziopharm and Intrexon and MD Anderson, which is my employer, will have an equity interest in both companies as a result of the transaction. As an inventor of the licensed technology, I will share in the proceeds of the consideration received by MD Anderson under the license in accordance with UT System Rules and MD Anderson policies and to that extent, I have a financial interest in both companies.

Increase in Patient Number Disrupts Manufacturing Scalability

THE UNIVERSITY OF TEXAS MD Anderson Cancer Center
Making Cancer History®



Point of Care and Off the Shelf Manufacturing

THE UNIVERSITY OF TEXAS MD Anderson Cancer Center
Making Cancer History®



Dual Distribution Approaches for CAR-T

THE UNIVERSITY OF TEXAS MD Anderson Cancer Center
Making Cancer History®



Registration Trials & Global Distribution with Multiple Pharma Partners

Steps Toward Point of Care Distribution

THE UNIVERSITY OF TEXAS MD Anderson Cancer Center
Making Cancer History®



Steps Toward Off the Shelf Distribution

THE UNIVERSITY OF TEXAS MD Anderson Cancer Center
Making Cancer History®





Portfolio of Effector Cells

THE UNIVERSITY OF TEXAS MD Anderson Cancer Center
Making Cancer History®

1. Chimeric Antigen Receptor (CAR^+) T cells:

Target cell surface tumor-associated antigens (TAAs) independent of HLA
- "Public" antigens

2. T Cell Receptor (TCR^+) cells:

Target intracellular TAAs dependent on HLA
- "Private" antigens

3. Natural Killer (NK) cells:

Target tumor with loss of HLA
- No "antigens"

Improving Therapeutic Potential of CAR T Cells

THE UNIVERSITY OF TEXAS MD Anderson Cancer Center
Making Cancer History®

CAR T Cells for improved potency and persistence

- Understanding of the effector cell biology
- Co-stimulation CAR with cytokine





Effector cells | Chimeric antigen receptor | Cytokine

Signals 1 & 2 | Signal 3

RTS® for Gene and Cell-based Therapies

THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center
Making Cancer History®



Building the Next-Generation of Inducible Cytokines

THE UNIVERSITY OF TEXAS MD Anderson Cancer Center
Making Cancer History®

Therapeutic potential of effector cells depends on recognition of tumor cells and recycling effector function in tumor microenvironment.



Management of Potential Toxicity through Inducible Immunoreceptor Expression

THE UNIVERSITY OF TEXAS MD Anderson Cancer Center
Making Cancer History®

Many attractive target antigens are expressed on normal cells



Advantages of Non-Viral Gene Integration

THE UNIVERSITY OF TEXAS MD Anderson Cancer Center
Making Cancer History®

***Sleeping Beauty* transposon/transposase system**

- Efficient and nimble gene transfer method
- Bypasses the cost, time, and complexity of viral-based delivery vectors



Manufacturing Platform Defines Specificity & Potency

THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center
Making Cancer History®





Eliminating HLA and TCR on CAR+ T Cells for Universal Donor

THE UNIVERSITY OF TEXAS MD Anderson Cancer Center
Making Cancer History®



Blood. 2013 Aug 22;122(8):1341-9
Blood. 2012 Jun 14;119(24):5697-705

Personalized Therapy for Disease and Patient

THE UNIVERSITY OF TEXAS MD Anderson Cancer Center
Making Cancer History®

Heterogeneity of tumor-associated antigen (TAA)



Infuse T cells with more than one specificity
Personalized for the disease

Infuse T cells with one or more specificity
Personalized for the patient
"N=1" trial paradigm

ZIOPHARM Oncology

An Accelerated Synthetic Immunology Pipeline

ZIOPHARM Oncology



An Accelerated Synthetic Immunology Pipeline

ZIOPHARM Oncology



Up to 5 CARs entering clinic in 2015

ZIOPHARM Oncology

The Future of Cancer Therapy

JP Morgan 33rd Annual Healthcare Conference

January 2015